Sector valuations Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 00:00:00 18/06/2026 +04			5-day change	1st Jan Change
2.980 ^USD	+1.71%		+1.02%	+8.36%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	Price to Book (Y)	PEG (Y)	EV / Sales (Y)	EV / EBITDA (Y)	EV / EBIT (Y)	Dividend Yield (Y)	Capi.($)
PERSPECTIVE THERAPEUTICS, INC.	-2.69x	1.32x	0.13x	365.63x	-1.2x	-1.22x	-.--%	340M
LONZA GROUP AG	29.79x	3.81x	1.32x	5.28x	16.37x	22.98x	1.1%	43.44B
REVOLUTION MEDICINES, INC.	-19.84x	14.48x	-0.59x	293.52x	-18.08x	-17.77x	-.--%	33.54B
IQVIA HOLDINGS INC.	20.77x	3.93x	4.31x	2.44x	10.54x	16.06x	-.--%	28.48B
BEONE MEDICINES AG	39.19x	5.85x	0.24x	3.88x	24.86x	29.42x	-.--%	29.2B
CELLTRION, INC.	29.31x	2.17x	0.86x	7.59x	19.53x	23.31x	0.42%	25.34B
MEDPACE HOLDINGS, INC.	26.83x	13.43x	2.33x	4.29x	19.54x	20.49x	-.--%	13.05B
EUROFINS SCIENTIFIC SE	21.72x	2.28x	0.75x	1.89x	8.33x	13.18x	1.23%	12.67B
IONIS PHARMACEUTICALS, INC.	-20.58x	306.9x	-0.4x	13.55x	-20.17x	-19.61x	-.--%	12.28B
ICON PUBLIC LIMITED COMPANY	22.8x	1.12x	0.2x	1.65x	10.01x	11.46x	-.--%	10.97B
TEMPUS AI, INC.	-24.23x	21.62x	-0.57x	5.9x	144.78x	-455.6x	-.--%	8.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	29.72x	2.66x	-0.1x	2.75x	10.74x	13.03x	-.--%	8.78B
BIO-TECHNE CORPORATION	47.17x	3.99x	0.31x	7.07x	20.04x	21.92x	0.58%	8.61B
ABIVAX	-22.96x	39.9x	1.13x	1745.04x	-24.9x	-25.51x	-.--%	8.16B
QIAGEN N.V.	17.45x	1.99x	2.16x	3.75x	10x	12.8x	-.--%	7.56B
ALKERMES PLC	-112.12x	4.03x	0.88x	4.63x	24.53x	147.2x	-.--%	7.42B
KYMERA THERAPEUTICS, INC.	-25.52x	6.57x	5.61x	71.68x	-16.09x	-15.51x	-.--%	7.39B
Average	3.34x	25.65x	1.09x	149.44x	14.05x	-11.96x	0.2%	15.65B
Weighted average by Cap.	11.68x	21.21x	1.11x	97.00x	12.48x	-0.73x	0.3%